2-Allyl-1,3-dioxolan | 38653-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: 2-Allyl-1,3-dioxolan
• 英文别名: 2-Allyl-dioxolan；1,3-Dioxolane, 2-(2-propenyl)-；2-prop-2-enyl-1,3-dioxolane
• CAS: 38653-49-5
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: URORFZFSRFKQKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Cyclic compounds
  申请人：——

  公开号：US20040142930A1

  公开（公告）日：2004-07-22

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, 1 wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  化合物的公式（I）或其药理学上可接受的盐，其中X为═CH—或═N—，Y为—NH—，—NR4—，—S—，—O—，—CH═N—，—N═CH—，—N═N—，—CH═CH—等，R1为较低的烷氧基，氨基，含N原子的杂环环，或者由含N原子的杂环环取代的羟基（每个都可以取代），R2为较低的烷基氨基基，可以由芳基取代，较低的烷氧基，可以由芳基取代，由含N原子的芳基取代的较低的烷氧基，R3为芳基，含N原子的杂环环，较低的烷基，较低的烷氧基，环状较低的烷氧基，由含N原子的杂环环取代的羟基，或者氨基（每个都可以取代），R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• [EN] GSK-3 INHIBITORS<br/>[FR] INHIBITEURS DE GSK-3
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015069594A1

  公开（公告）日：2015-05-14

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  披露通常涉及到公式I的化合物，包括它们的盐，以及使用这些化合物治疗与GSK-3相关疾病的组合物和方法。
• [EN] MACROCYCLIZATION REACTIONS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B<br/>[FR] RÉACTIONS DE MACROCYCLISATION ET INTERMÉDIAIRES UTILES DANS LA SYNTHÈSE D'ANALOGUES DE L'HALICHONDRINE B
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2015066729A1

  公开（公告）日：2015-05-07

  The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

  该发明提供了一种通过大环化策略合成厄立宾或其药用可接受盐（例如，厄立宾甲磺酸盐）的方法。本发明的大环化策略涉及将非大环中间体经过碳-碳键形成反应（例如，烯化反应（例如，Horner-Wadsworth-Emmons烯化反应）、迪克曼反应、催化环闭合烯烃交换反应，或Nozaki-Hiyama-Kishi反应）以获得大环中间体。该发明还提供了在合成厄立宾或其药用可接受盐时作为中间体有用的化合物以及制备这些化合物的方法。
• [EN] PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF<br/>[FR] RÉACTION DE PRINS ET DE COMPOSÉS UTILES DANS LA SYNTHÈSE DE MACROLIDES D'HALICHONDRINE ET DE SES ANALOGUES
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2019136145A1

  公开（公告）日：2019-07-11

  The invention provides methods utilizing Prins reaction in the preparation of compounds that may be useful as intermediates in the synthesis of halichondrin macrolides and analogs thereof. The invention also provides compounds that may be useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.

  该发明提供了利用普林斯反应在合成半人马毒素大环内酯及其类似物中可能用作中间体的化合物的方法。该发明还提供了可能用作半人马毒素大环内酯合成中间体的化合物以及其制备方法。
• PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY LIQUID PHASE HYDROGENOLYSIS OF CYCLIC ACETALS OR CYCLIC KETALS
  申请人：Billodeaux Damon Ray

  公开号：US20120330069A1

  公开（公告）日：2012-12-27

  A liquid phase hydrogenolysis of acetal compounds such as cyclic acetals and cyclic ketals are fed to a reaction zone and reacted in the presence of a noble metal catalyst supported on a carbon or silica support to make hydroxy ether mono-hydrocarbons in high selectivity, without the necessity to use acidic co-catalysts such as phosphorus containing acids or stabilizers such as hydroquinone.

  将环丙二醛和环酮等缩醛类化合物进行液相氢解反应，将其送入反应区，在贵金属催化剂的存在下，在碳或硅基负载物上反应，高选择性地制备羟基醚单一碳氢化合物，无需使用含磷酸类酸或稳定剂如羟基苯酚。